Immunotherapy for Stage III NSCLC: Durvalumab and Beyond

Orla Fitzpatrick,1 Jarushka Naidoo1,2 1Department of Oncology, Beaumont Hospital, RCSI University of Health Sciences, Dublin, Ireland; 2Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, 21231, USACorrespondence: Jarushka NaidooBeaumont Hosp...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fitzpatrick O, Naidoo J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	lung cancer immunotherapy durvalumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/01f89d883ac44a82874552e46fc7f16f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:01f89d883ac44a82874552e46fc7f16f
record_format	dspace
spelling	oai:doaj.org-article:01f89d883ac44a82874552e46fc7f16f2021-12-02T19:31:58ZImmunotherapy for Stage III NSCLC: Durvalumab and Beyond1179-2728https://doaj.org/article/01f89d883ac44a82874552e46fc7f16f2021-11-01T00:00:00Zhttps://www.dovepress.com/immunotherapy-for-stage-iii-nsclc-durvalumab-and-beyond-peer-reviewed-fulltext-article-LCTThttps://doaj.org/toc/1179-2728Orla Fitzpatrick,1 Jarushka Naidoo1,2 1Department of Oncology, Beaumont Hospital, RCSI University of Health Sciences, Dublin, Ireland; 2Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, 21231, USACorrespondence: Jarushka NaidooBeaumont Hospital, Beaumont Road, Dublin, 9, Ireland, Tel +353 1 809-3000Email jnaidoo1@jhmi.eduAbstract: Immunocheckpoint inhibitors (ICIs) have altered the treatment landscape of a wide range of malignancies, including non–small cell lung cancer (NSCLC). This class of agents inhibits the interaction between PD1 and PDL1, and was shown to be efficacious in the landmark PACIFIC trial with 1 year of maintenance durvalumab (anti-PDL1 antibody). This trial demonstrated that its use as a consolidation treatment given after definitive chemoradiotherapy improved progression free survival and overall survival compared to standard-of-care treatment. In this review, we discuss both clinical trial and real-world data that have been published since PACIFIC that support the use of durvalumab for stage III unresectable NSCLC. In addition, we highlight specific populations that may require special considerations for the use of durvalumab in this setting, such as oncogene-addicted NSCLC, the toxicity of immunotherapy, and future directions in ICI research in stage III NSCLC.Keywords: lung cancer, immunotherapy, durvalumabFitzpatrick ONaidoo JDove Medical Pressarticlelung cancerimmunotherapydurvalumabNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 12, Pp 123-131 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	lung cancer immunotherapy durvalumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	lung cancer immunotherapy durvalumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Fitzpatrick O Naidoo J Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
description	Orla Fitzpatrick,1 Jarushka Naidoo1,2 1Department of Oncology, Beaumont Hospital, RCSI University of Health Sciences, Dublin, Ireland; 2Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, 21231, USACorrespondence: Jarushka NaidooBeaumont Hospital, Beaumont Road, Dublin, 9, Ireland, Tel +353 1 809-3000Email jnaidoo1@jhmi.eduAbstract: Immunocheckpoint inhibitors (ICIs) have altered the treatment landscape of a wide range of malignancies, including non–small cell lung cancer (NSCLC). This class of agents inhibits the interaction between PD1 and PDL1, and was shown to be efficacious in the landmark PACIFIC trial with 1 year of maintenance durvalumab (anti-PDL1 antibody). This trial demonstrated that its use as a consolidation treatment given after definitive chemoradiotherapy improved progression free survival and overall survival compared to standard-of-care treatment. In this review, we discuss both clinical trial and real-world data that have been published since PACIFIC that support the use of durvalumab for stage III unresectable NSCLC. In addition, we highlight specific populations that may require special considerations for the use of durvalumab in this setting, such as oncogene-addicted NSCLC, the toxicity of immunotherapy, and future directions in ICI research in stage III NSCLC.Keywords: lung cancer, immunotherapy, durvalumab
format	article
author	Fitzpatrick O Naidoo J
author_facet	Fitzpatrick O Naidoo J
author_sort	Fitzpatrick O
title	Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
title_short	Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
title_full	Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
title_fullStr	Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
title_full_unstemmed	Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
title_sort	immunotherapy for stage iii nsclc: durvalumab and beyond
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/01f89d883ac44a82874552e46fc7f16f
work_keys_str_mv	AT fitzpatricko immunotherapyforstageiiinsclcdurvalumabandbeyond AT naidooj immunotherapyforstageiiinsclcdurvalumabandbeyond
_version_	1718376419703128064

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond

Ejemplares similares